{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"24"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"25"}],"units":"Participants"}],"description":"We define a tolerability success as a patient completing the first course of therapy without experiencing a grade 4 or 5 non-hematologic toxicity.","groups":[{"description":"All eligible patients received the first cycle of CPX-351 for remission induction.","id":"OG000","title":"CPX-351 (Vyxeos)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Patients who completed the first cycle.","reportingStatus":"POSTED","timeFrame":"Adverse events will be monitored from the time of first study intervention or treatment until the completion of the first course of therapy","title":"Tolerability Success Rate (TSR) for the First Course of Chemotherapy","type":"PRIMARY","unitOfMeasure":"Participants"}